Gefitinib

SIGMA/SML1657 - ≥98% (HPLC)

Synonym: N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; ZD1839

CAS Number: 184475-35-2
Empirical Formula (Hill Notation): C₂₂H₂₄ClFN₄O₃
Molecular Weight: 446.90
MDL Number: MFCD04307832
Linear Formula: C₂₂H₂₄ClFN₄O₃
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-SML1657-10MG	10 mg	$108.00 1/EA	Add To Favorites
45-SML1657-50MG	50 mg	$435.00 1/EA	Add To Favorites

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98% (HPLC)
color	white to beige
form	powder
InChI	1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
InChI key	XGALLCVXEZPNRQ-UHFFFAOYSA-N
Quality Level	100
SMILES string	COC(C=C(N=CN=C1NC2=CC(Cl)=C(F)C=C2)C1=C3)=C3OCCCN4CCOCC4
solubility	DMSO: 10 mg/mL, clear
storage temp.	room temp

Application:	Gefitinib has been used : • To study its effective use in endometrial cancer therapy • Cell proliferation, cell cycle and apoptosis assays • Cell viability assay and colony formation assay
Biochem/physiol Actions:	Gefitinib is a selective epidermal growth factor receptor tyrosine kinase (EGFR TK) inhibitor. Gefitinib has antineoplastic activity, and has been approved for the treatment on non-small cell lung cancer (NSCLC). Gefitinib has a higher affinity for ATP (adenosine triphosphate) binding site in the EGFR tyrosine kinase domain than ATP. Hence, gefitinib is known to inhibit the progression of endometrial cancer.
Packaging:	10, 50 mg in glass bottle

Symbol	GHS07
Signal word	Warning
Hazard statements	H302 - H315 - H319 - H335
Precautionary statements	P301 + P312 + P330 - P305 + P351 + P338
RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥98% (HPLC)
Storage Temp.	room temp
UNSPSC	12352200

To Order From a Quote